W. M. Santoso, Andhy Indriyono, B. Munir, Alidha Nur Rakhman, M. Husna
{"title":"COMPARATIVE OF INTRAARTICULAR INJECTION BETWEEN DEXTROSE PROLOTHERAPY VERSUS TRIAMCINOLONE ACETONIDE IN KNEE OSTEOARTHRITIS","authors":"W. M. Santoso, Andhy Indriyono, B. Munir, Alidha Nur Rakhman, M. Husna","doi":"10.21776/ub.jphv.2020.001.02.1","DOIUrl":null,"url":null,"abstract":"Knee osteoarthritis (OA) is one of the most common cartilage degenerative disorders that is a major problem because it causes chronic pain and disability. Therefore the method of treatment and prevention of old age is a big challenge. The results of Dextrose Prolotherapy compared to Triamcinolone therapy research are still varied. Objective: to compare the effectiveness of Dextrose Prolotherapy and Triamcinolone Acetonide (TA) in the treatment of moderate knee knee OA.True experimental single blind study, at the Neurology Polyclinic Dr. Saiful Anwar General Hospital Malang for 6 months (July-December 2019). Group I; Dextrose Prolotherapy (15%) intraarticularly injected 3 times every 4 weeks and group II; TA onetime intraarticular injection. The parameters studied were The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score, Numeric Rating Scale (NRS), and Range of Motion (ROM), weeks 0, 4, 8, 12 and 24. Forty samples consisted of; the 20 samples of the Dextrose Prolotherapy group consisted of; male: female = 2 (10%): 18 (90%), age 62.4 + 7.28, BMI 25.6 + 3.69 kg / m2, pain duration 22.35 + 20.10 months, history of physiotherapy 40.27 + 20.79 times. Kellgren–Lawrence osteoarthritis severity grade II; 17 (85%), grade III 3 (15%). TA group; male: female = 5 (25%):15 (75%), age 62.5 + 9.02, BMI 28.4 + 5.01 kg/m2, pain duration 15.95 + 16.55 months, history of physiotherapy 34 + 24.87 times. Kellgren – Lawrence osteoarthritis severity grade II; 18 (90%), grade III; 2 (10%). Comparison of NRS at rest Dextrose Prolotherapy vs TA of week 4 (2.60 vs 1.25), week 8 (1.65 vs 1.40), week 12 (0.8 vs 2.05), week 24 (0.75 vs 3.35). Comparison of NRS during activity Dextrose Prolotherapy vs TA week 4 (4.45 vs 3.35), week 8 (3.25 vs 3.55), week 12 (2.55 vs 4.30), week 24 (2.55 vs 5.80). Comparison of ROM flexion Dextrose Prolotherapy vs TA week 4 (127.05° vs 123.60°), week 8 (130.85° vs 122.95°), week 12 (130.85° vs 122.95°), week 24 (131.05° vs 122.10°). Comparison of WOMAC score Dextrose Prolotherapy vs TA week 4 (30.05 vs 22.45), week 8 (22.90 vs 23.95), week 12 (19.30 vs 29.05), week 24 (18.95 vs 35.40). Intraarticular Injection Dextrose Prolotherapy is more effective for the long term based on pain scale NRS, WOMAC score and ROM. Whereas short-term TA is more effective than Dextrose Prolotherapy. Keyword : Osteoarthritis, Dextrose Prolotherapy, Triamcinolone Acetonide","PeriodicalId":126692,"journal":{"name":"JPHV (Journal of Pain, Vertigo and Headache)","volume":"20 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JPHV (Journal of Pain, Vertigo and Headache)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21776/ub.jphv.2020.001.02.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Knee osteoarthritis (OA) is one of the most common cartilage degenerative disorders that is a major problem because it causes chronic pain and disability. Therefore the method of treatment and prevention of old age is a big challenge. The results of Dextrose Prolotherapy compared to Triamcinolone therapy research are still varied. Objective: to compare the effectiveness of Dextrose Prolotherapy and Triamcinolone Acetonide (TA) in the treatment of moderate knee knee OA.True experimental single blind study, at the Neurology Polyclinic Dr. Saiful Anwar General Hospital Malang for 6 months (July-December 2019). Group I; Dextrose Prolotherapy (15%) intraarticularly injected 3 times every 4 weeks and group II; TA onetime intraarticular injection. The parameters studied were The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score, Numeric Rating Scale (NRS), and Range of Motion (ROM), weeks 0, 4, 8, 12 and 24. Forty samples consisted of; the 20 samples of the Dextrose Prolotherapy group consisted of; male: female = 2 (10%): 18 (90%), age 62.4 + 7.28, BMI 25.6 + 3.69 kg / m2, pain duration 22.35 + 20.10 months, history of physiotherapy 40.27 + 20.79 times. Kellgren–Lawrence osteoarthritis severity grade II; 17 (85%), grade III 3 (15%). TA group; male: female = 5 (25%):15 (75%), age 62.5 + 9.02, BMI 28.4 + 5.01 kg/m2, pain duration 15.95 + 16.55 months, history of physiotherapy 34 + 24.87 times. Kellgren – Lawrence osteoarthritis severity grade II; 18 (90%), grade III; 2 (10%). Comparison of NRS at rest Dextrose Prolotherapy vs TA of week 4 (2.60 vs 1.25), week 8 (1.65 vs 1.40), week 12 (0.8 vs 2.05), week 24 (0.75 vs 3.35). Comparison of NRS during activity Dextrose Prolotherapy vs TA week 4 (4.45 vs 3.35), week 8 (3.25 vs 3.55), week 12 (2.55 vs 4.30), week 24 (2.55 vs 5.80). Comparison of ROM flexion Dextrose Prolotherapy vs TA week 4 (127.05° vs 123.60°), week 8 (130.85° vs 122.95°), week 12 (130.85° vs 122.95°), week 24 (131.05° vs 122.10°). Comparison of WOMAC score Dextrose Prolotherapy vs TA week 4 (30.05 vs 22.45), week 8 (22.90 vs 23.95), week 12 (19.30 vs 29.05), week 24 (18.95 vs 35.40). Intraarticular Injection Dextrose Prolotherapy is more effective for the long term based on pain scale NRS, WOMAC score and ROM. Whereas short-term TA is more effective than Dextrose Prolotherapy. Keyword : Osteoarthritis, Dextrose Prolotherapy, Triamcinolone Acetonide
膝骨关节炎(OA)是最常见的软骨退行性疾病之一,是一个主要问题,因为它会导致慢性疼痛和残疾。因此,治疗和预防老年的方法是一个很大的挑战。与曲安奈德治疗相比,葡萄糖前列洛治疗的研究结果仍存在差异。目的:比较葡萄糖prolove与曲安奈德(Triamcinolone Acetonide, TA)治疗中度膝关节炎的疗效。真正的实验性单盲研究,在麻琅的神经病学综合诊所赛弗·安华医生综合医院进行了6个月(2019年7月至12月)。组我;葡萄糖prololotherapy(15%)关节内注射3次,每4周和II组;TA一次性关节内注射。研究的参数是西安大略省和麦克马斯特大学骨关节炎指数(WOMAC)评分、数值评定量表(NRS)和活动范围(ROM),第0、4、8、12和24周。40个样本包括;葡萄糖前驱治疗组20例:男:女= 2(10%):18(90%),年龄62.4 + 7.28,BMI 25.6 + 3.69 kg / m2,疼痛持续时间22.35 + 20.10个月,物理治疗史40.27 + 20.79次。Kellgren-Lawrence骨关节炎严重程度II级;17 (85%), III级3(15%)。助教组;男:女= 5(25%):15(75%),年龄62.5 + 9.02,体重指数28.4 + 5.01 kg/m2,疼痛持续时间15.95 + 16.55个月,物理治疗史34 + 24.87次。Kellgren - Lawrence骨关节炎严重程度II级;18人(90%),三级;2(10%)。葡萄糖前治疗与TA的静息NRS比较:第4周(2.60 vs 1.25)、第8周(1.65 vs 1.40)、第12周(0.8 vs 2.05)、第24周(0.75 vs 3.35)。活动葡萄糖前体治疗与TA第4周(4.45 vs 3.35)、第8周(3.25 vs 3.55)、第12周(2.55 vs 4.30)、第24周(2.55 vs 5.80)期间NRS的比较。ROM屈曲葡萄糖前疗法与TA的比较,第4周(127.05°vs 123.60°),第8周(130.85°vs 122.95°),第12周(130.85°vs 122.95°),第24周(131.05°vs 122.10°)。葡萄糖前治疗与TA治疗的WOMAC评分比较:第4周(30.05 vs 22.45)、第8周(22.90 vs 23.95)、第12周(19.30 vs 29.05)、第24周(18.95 vs 35.40)。基于疼痛量表NRS、WOMAC评分和ROM,关节内注射葡萄糖前驱治疗长期更有效,而短期TA比葡萄糖前驱治疗更有效。关键词:骨关节炎,葡萄糖Prolotherapy,曲安奈德